Sunday 18 October 2026
Export ATOS’s income statement to Excel — free account
Atossa Therapeutics, Inc.
ATOS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 9.48% and free cash flow fell 32.9%, each against the same quarter a year earlier.
2.91
0.26
+9.81%
Follow ATOS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(48.89%) | (62.74%) | (78.58%) | (89.23%) | |
| (43.90%) | (56.06%) | (69.26%) | (77.91%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (3,918.83%) | |
Return on Tangible Assets |
(63.60%) | (93.06%) | (128.86%) | (147.54%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(3.05) | (3.46) | (3.87) | (4.01) | |
Free Cash Flow |
(26.29) | (29.78) | (33.38) | (35.77) | |
Capital Expenditures |
(0.02) | (0.02) | — | — | |
| Other line items | |||||
Cash ROIC |
(25.84%) | (36.88%) | (53.57%) | (67.45%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
— | 0.00 | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
— | 0.00 | — | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.87 | 0.86 | 0.89 | 0.95 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(1.00) | (1.44) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.05) | (3.46) | (3.87) | (4.01) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates · fundamentals updated 2 Oct 2026